5229-40-3 Usage
Description
5-(Chloromethyl)-2-phenylpyridine is an organic compound with the molecular formula C12H10ClN. It is a derivative of pyridine, featuring a chloromethyl group at the 5th position and a phenyl group at the 2nd position. 5-(CHLOROMETHYL)-2-PHENYLPYRIDINE is known for its potential applications in the synthesis of various biologically active molecules.
Uses
Used in Pharmaceutical Industry:
5-(Chloromethyl)-2-phenylpyridine is used as an intermediate in the preparation of pyrrolyland pyrazolylalkanoic acid derivatives, which are essential in biological studies. These derivatives have potential applications in the development of new drugs and therapeutic agents, targeting various diseases and medical conditions.
Used in Chemical Research:
In the field of chemical research, 5-(Chloromethyl)-2-phenylpyridine serves as a valuable building block for the synthesis of more complex molecules with diverse chemical properties. Its unique structure allows for further functionalization and modification, making it a versatile compound for exploring new chemical reactions and developing novel molecular architectures.
Check Digit Verification of cas no
The CAS Registry Mumber 5229-40-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,2,2 and 9 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 5229-40:
(6*5)+(5*2)+(4*2)+(3*9)+(2*4)+(1*0)=83
83 % 10 = 3
So 5229-40-3 is a valid CAS Registry Number.
InChI:InChI=1/C12H10ClN/c13-8-10-6-7-12(14-9-10)11-4-2-1-3-5-11/h1-7,9H,8H2
5229-40-3Relevant articles and documents
Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility
Ang, Chee Wei,Tan, Lendl,Sykes, Melissa L.,Abugharbiyeh, Neda,Debnath, Anjan,Reid, Janet C.,West, Nicholas P.,Avery, Vicky M.,Cooper, Matthew A.,Blaskovich, Mark A. T.
, p. 15726 - 15751 (2020/12/02)
Following the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is now a renewed interest in bicyclic nitroimidazole scaffolds as a source of therapeutics against infectious diseases. We recently described a nitroimidazopyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting additional efforts to generate analogs with improved solubility and enhanced potency. The key pendant aryl substituent was modified by (i) introducing polar functionality to the methylene linker, (ii) replacing the terminal phenyl group with less lipophilic heterocycles, or (iii) generating extended biaryl side chains. Improved antitubercular and antitrypanosomal activity was observed with the biaryl side chains, with most analogs achieved 2- to 175-fold higher activity than the monoaryl parent compounds, with encouraging improvements in solubility when pyridyl groups were incorporated. This study has contributed to understanding the existing structure-activity relationship (SAR) of the nitroimidazopyrazinone scaffold against a panel of disease-causing organisms to support future lead optimization.